Healthcare

Pharnext: Consolidation Of Shares Making Up Its Share Capital

  • March 24, 2023 08:33 AM CET | Reuters
 Pharnext: Consolidation Of Shares Making Up Its Share Capital

March 24 (Reuters) - Pharnext SA: * CONSOLIDATION OF SHARES MAKING UP ITS SHARE CAPITAL, AT RATE OF 1 NEW SHARE AGAINST 10,000 OLD ONES * OPERATIONS WILL BEGIN ON APRIL 9, 2023 AND COMPLETE ON MAY 9,

Read More...
UPDATE 5-Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data

UPDATE 5-Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data

  • March 23, 2023 01:24 PM CET | Reuters

* Drug meets primary and all secondary goals in COPD trial * Previous peak sales estimate of 13 bln euros was without COPD * Drug could be first new COPD treatment in over a decade (Adds Regeneron

Read More...
Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data

Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data

  • March 23, 2023 09:42 AM CET | Reuters

* Drug meets primary and all secondary goals in COPD trial * Previous peak sales estimate of 13 bln euros was without COPD * Drug could be first new COPD treatment in over a decade (Adds share price

Read More...
Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data

Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data

  • March 23, 2023 09:04 AM CET | Reuters

* Drug meets primary and all secondary goals in COPD trial * Previous peak sales estimate of 13 bln euros was without COPD * Drug could be first new COPD treatment in over a decade (Adds analyst

Read More...
Sanofi, Regeneron's Dupixent shows promise as 'smoker's lung' drug

Sanofi, Regeneron's Dupixent shows promise as 'smoker's lung' drug

  • March 23, 2023 08:14 AM CET | Reuters

* Drug meets primary and all secondary goals in COPD trial * Previous peak sales estimate of 13 bln eur was without COPD * Drug could be first new COPD treatment in over decade (Adds Dupixent sales,

Read More...
Poxel Announces Cash Runway Extended Through Q2 2025

Poxel Announces Cash Runway Extended Through Q2 2025

  • March 23, 2023 07:46 AM CET | Reuters

March 23 (Reuters) - Poxel Sa: * POXEL ANNOUNCES CASH RUNWAY EXTENDED THROUGH Q2 2025 BASED UPON DEBT RESTRUCTURING AGREEMENT AND NEW EQUITY-LINKED FINANCING FACILITY * COMPANY EXPECTS THAT ITS

Read More...
Sanofi, Regeneron's Dupixent shows promise as 'smoker's lung' drug

Sanofi, Regeneron's Dupixent shows promise as 'smoker's lung' drug

  • March 23, 2023 07:45 AM CET | Reuters

(Releads, adds background on Dupixent) By Ludwig Burger and Juby Babu March 23 (Reuters) - Sanofi's asthma and eczema drug Dupixent met all targets in a trial to treat "smoker's lung", giving a major

Read More...
Poxel FY Net Loss EUR 31.4 Mln

Poxel FY Net Loss EUR 31.4 Mln

  • March 23, 2023 07:33 AM CET | Reuters

March 23 (Reuters) - Poxel SA: * POXEL REPORTS FINANCIAL RESULTS FOR FULL YEAR 2022 AND PROVIDES CORPORATE UPDATE * POXEL REPORTED REVENUES OF EUR 0.674 MILLION FOR YEAR ENDED DECEMBER 31, 2022, * NET

Read More...
Sanofi Says Dupixent Shows Reduction In Exacerbations In Phase 3 Trial As A Potential Treatment For COPD

Sanofi Says Dupixent Shows Reduction In Exacerbations In Phase 3 Trial As A Potential Treatment For COPD

  • March 23, 2023 07:11 AM CET | Reuters

March 23 (Reuters) - Sanofi SA: * SANOFI-DUPIXENT SHOWS REDUCTION IN EXACERBATIONS IN PHASE 3 TRIAL AS A POTENTIAL TREATMENT FOR COPD * SANOFI-PHASE 3 TRIAL OF DUPIXENT SHOWED SIGNIFICANT REDUCTION (

Read More...
Innate Pharma End-2022 Cash Position Of EUR 136.6 Million

Innate Pharma End-2022 Cash Position Of EUR 136.6 Million

  • March 23, 2023 07:09 AM CET | Reuters

March 23 (Reuters) - Innate Pharma SA: * CASH POSITION OF EUR 136.6 MILLION AS OF DECEMBER 31, 2022 * REVENUE AND OTHER INCOME FROM CONTINUING OPERATIONS AMOUNTED TO EUR 57.7M IN 2022 (2021: EUR 24.7M

Read More...
Valneva Eyes EUR 220-260 Mln In Revenues And Other Income In 2023

Valneva Eyes EUR 220-260 Mln In Revenues And Other Income In 2023

  • March 23, 2023 07:07 AM CET | Reuters

March 23 (Reuters) - Valneva SE: * VALNEVA REPORTS FULL YEAR 2022 RESULTS AND PROVIDES CORPORATE UPDATES * STRONG CASH POSITION OF EUR 289.4MILLION AT DECEMBER 31, 2022 * TOTAL REVENUES OF EUR 361.3

Read More...